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In half of all human cancers, the tumor sup-
pressor p53 protein is damaged by somatic mu-
tation in tumor cells (1). Furthermore, germline 
alterations of the TP53 gene encoding the p53 
protein have been observed in the majority of 
families with the Li-Fraumeni syndrome, a rare 
dominantly inherited disorder (2). This syn-
drome is characterized by early-onset cancer. 
The p53 protein is at the center of cell regula-
tory pathways, infl  uencing transcription and ac-
tivity of several replication and transcription 
factors. In case of UV radiation, protoonco-
gene activation, or DNA damage, p53 is acti-
vated. Normally, this leads to activation of 
repair mechanisms, induction of cell cycle arrest, 
and the prevention of cancer growth via apop-
tosis; when p53 is damaged, cancer cells continue 
to multiply.
In genomic DNA in exon 4 of the TP53 
gene, a polymorphism causing an Arg72Pro 
substitution has genotype frequencies in Eu-
ropeans of  60, 30, and 10% for Arg/Arg, 
Arg/Pro, and Pro/Pro, respectively (3). This 
sub  stitution is in the putative SH3 binding 
domain of p53, infl  uencing binding capacity and 
thereby functional properties of p53 (4). The 
Arg allele increases the ability of p53 to locate to 
mitochondria and induce cellular death, whereas 
the Pro allele exhibits a lower apoptotic poten-
tial and an increased cellular arrest in G1 of the 
cell cycle (5–7). Thus, this is an important gain-
of-function polymorphism at the cellular level. 
Increased levels of p53 activity protect against 
cancer at the cost of premature aging (8–10), 
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or other life-threatening diseases.
CORRESPONDENCE
Børge Grønne Nordestgaard:
brno@heh.regionh.dk
D. Dynnes Ørsted and S.E. Bojesen contributed equally to 
this paper.
The online version of this article contains supplemental material.1296  P53 ARG72PRO, LONGEVITY, AND CANCER | Dynnes Ørsted et al.
indicating that the level of expression of p53 infl  uences not 
only local cancer development but also degenerative pro-
cesses in the whole organism.
Collectively, these observations suggest that the p53 Arg-
72Pro polymorphism may infl  uence longevity, prognosis 
after a cancer diagnosis, and risk of cancer. These three hy-
potheses were tested in the present prospective study of 
>9,000 individuals from the Danish general population with 
12, 12, and 55 yr of follow-ups, respectively.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
In this large cohort from the general population, we show 
that a well-known functional polymorphism in the tumor 
suppressor p53 protein leads to increased longevity and in-
creased survival after a diagnosis of cancer or other life-threat-
ening diseases, but not to decreased risk of cancer. Among 
9,219 individuals from the Danish general population, we 
observed 2,264 deaths as well as 2,048 participants with a fi  rst 
cancer. For the Arg72Pro polymorphism, 54, 39, and 7% 
were Arg/Arg homozygotes, Arg/Pro heterozygotes, and 
Pro/Pro homozygotes, respectively (test for Hardy-Weinberg 
equilibrium: P = 0.93). Conventional risk factors for death, 
cancer, and other common multifactorial diseases were 
equally distributed between individuals with the three diff  er-
ent genotypes (Table I).
Longevity
The overall 12-yr survival after blood sampling was increased 
in Arg/Pro heterozygotes with 3% (P = 0.003) and in Pro/Pro 
homozygotes with 6% (P = 0.002) versus Arg/Arg homozy-
gotes (Fig. 1, A and C). Death incidences from any cause were 
270, 238, and 210 per 10,000 person-years (the number of 
collective years that the individuals in a particular group were 
observed) in Arg/Arg homozygotes, Arg/Pro heterozygotes, 
and Pro/Pro homozygotes, respectively (Table II). This cor-
responds to gender- and age-adjusted hazard ratios for death 
from any cause in Arg/Pro heterozygotes and Pro/Pro ver-
sus Arg/Arg homozygotes of 0.88 (95% confi  dence interval 
[CI]: 0.81–0.96; P = 0.005) and 0.82 (0.68–0.97; P = 0.02), 
respectively. In accordance with this, the frequency of Pro/
Pro homozygotes and the Pro allele appeared to increase with 
increasing age toward 90 yr (Figs. S2 and S3, available at 
http://www.jem.org/cgi/content/full/jem.20062476/DC1). 
The frequency of Pro alleles rises when the participants with 
advancing age begin to die in considerable numbers. This is 
also what can be seen in the Kaplan-Meyer curves in Fig. 1 
and in the Cox regressions in Table II.
This reduction in risk of death translates into an increased 
median survival of 2 and 3 yr for Arg/Pro heterozygotes 
and Pro/Pro versus Arg/Arg homozygotes (Fig. 1, B and C). 
Figure 1.  12-yr survival and longevity of the general population 
by p53 Arg72Pro genotype. Death endpoints were collected from the 
Danish Civil Registration System, which is 100% complete. (A) For 12-yr 
survival, follow-up started at blood sampling and ended at death, emigra-
tion, or March 11, 2004, whichever came fi  rst. (B) For longevity using left-
truncated age, follow-up started at blood sampling and ended at death, 
emigration, or March 11, 2004, whichever came fi  rst. (C) Comparison of 
the effect of p53 Arg72Pro genotype with that of smoking status on 
12-yr survival and median survival in the same population. Arg/Arg homozy-
gotes are in blue, Arg/Pro heterozygotes are in red, and Pro/Pro homozy-
gotes are in green.
Table I.  Basic characteristics according to p53 Arg72Pro genotype in individuals in the general population
Characteristic Arg/Arg Arg/Pro Pro/Pro
Number (%) 4,934 (54) 3,623 (39) 662 (7)
Women (%) 55 55 56
Age (yr) 58 ± 15 58 ± 15 57 ± 15
Total tobacco consumption (pack-yearsa) 23 ± 24 22 ± 24 23 ± 23
Current or former smoker (%) 78 76 78
Body mass index (kg/m2) 25 ± 4 25 ± 4 25 ± 4
Alcohol (g/wk) 112 ± 147 113 ± 151 106 ± 133
Plasma cholesterol (mmol/liter) 6.2 ± 1.3 6.1 ± 1.3 6.1 ± 1.3
Systolic blood pressure (mmHg) 139 ± 23 138 ± 22 137 ± 22
Physically inactive (%)  12 12 14
Variables expressed as mean ± standard deviation or proportion were collected at the 1991–1994 examination of the Copenhagen City Heart Study. Statistical comparisons 
between the three genotype groups were made using two-sided Mann-Whitney U test, Pearson’s χ2 test, or Student’s t test on untransformed or log-transformed parameters 
as appropriate. No parameter had differences that were statistically signifi  cant among the three genotype groups.
aPack-years indicates the average number of packs of cigarettes smoked daily by a person multiplied by the number of years that person has been a smoker.JEM VOL. 204, June 11, 2007  1297
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For comparison, the median survival was 6 and 11 yr longer in 
former smokers and people who had never been smokers versus 
smokers (Fig. 1 C). Thus, the eff  ect of the Arg72Pro polymor-
phism is equivalent to a quarter of the mean survival diff  erence 
between smokers and nonsmokers, the most   important envi-
ronmental factor aff  ecting longevity in developed countries.
In accordance with our data, in the Leiden 85-plus study, 
Pro/Pro versus Arg/Arg homozygotes were associated with 
a 1.41-fold (95% CI: 1.03–1.92) increased survival among 
1,226 participants 85 yr or older followed for 5–10 yr (10). 
A 1.41-fold–increased survival is equivalent to a 0.71-fold risk 
of mortality, where we observed a 0.82-fold risk of mortality 
in Pro/Pro versus Arg/Arg homozygotes (Table II). In con-
trast to our study, the former study (10) did not observe de-
creased mortality in Arg/Pro heterozygotes versus Arg/Arg 
homozygotes; however, that study had less statistical power 
than the present study.
Genetic variations in modifi   ers of p53 like ATM and 
MDM2 could have an impact on the eff  ect of p53 Arg72Pro 
on mortality. However, the Ser49Cys and Ser707Pro poly-
morphisms of ATM and the −309 T/G polymorphism of the 
MDM2 promoter did not interact with the eff  ect of the 
Arg72Pro polymorphism on mortality (Fig. S4, available at 
http://www.jem.org/cgi/content/full/jem.20062476/DC1).
Survival after a diagnosis of cancer
We next examined whether the increased longevity was ex-
plained by a better prognosis in Arg/Pro heterozygotes and 
Pro/Pro versus Arg/Arg homozygotes after the diagnosis of 
cancer, cardiovascular disease, or other life-threatening dis-
eases. The cumulative 5-yr mortality after a cancer diagnosis 
was reduced in Arg/Pro heterozygotes and Pro/Pro versus 
Arg/Arg homozygotes by 9% (P = 0.003) and 13% (P = 
0.03; Fig. 2). The reduced 5-yr mortality corresponds to a 
decreased gender- and age-adjusted hazard ratio for death 
after a diagnosis of cancer of 0.87 (95% CI: 0.77–0.98) in 
Arg/Pro heterozygotes and 0.74 (0.56–0.98) in Pro/Pro versus 
Arg/Arg homozygotes (Table II). The equivalent hazard 
ratios for death were 0.95 (0.85–1.06) and 0.85 (0.69–1.05) 
after a diagnosis of cardiovascular disease and 0.88 (0.81–0.97) 
and 0.81 (0.68–0.98) after a diagnosis of another life-threat-
ening disease, respectively. Thus, the increased longevity as-
sociated with the Arg72Pro polymorphism may be due to 
increased survival after a diagnosis of cancer or other life-
threatening diseases.
In the Leiden 85-plus study, Pro/Pro versus Arg/Arg ho-
mozygotes had a hazard ratio of 0.59 (95% CI: 0.41–0.85) for 
death from all causes but cancer, but a nonsignifi  cant increase 
in mortality from cancer (10). However, this data is not di-
rectly comparable with ours, as we studied mortality after a di-
agnosis of cancer and other life-threatening diseases. In other 
words, we studied prognosis among those with disease, whereas 
the former study addressed cause-specifi  c mortality. Neverthe-
less, we cannot totally exclude the possibility that our fi  nding 
of increased survival after a diagnosis of cancer or other life-
threatening diseases could represent a chance fi  nding, as p-values 
only range from 0.03 to 0.007, and because this has not previ-
ously been shown by another independent group.
Table II.  Mortality, mortality after disease, and morbidity according to p53 Arg72Pro genotype in the general population
Arg/Arg Arg/Pro Pro/Pro
Endpoint Participants Incidents
Incidence 
n/10,000 
person-yearsa
HR
Incidence 
n/10,000 
person-yearsa
HR 
(95% CI)
p-value
Incidence 
n/10,000 
person-yearsa
HR 
(95% CI)
p-value
Mortality 9,219 2,264 270 1.0 238
0.88 
(0.81–0.96)
0.005a 210
0.82 
(0.68–0.97)
0.02
Mortality after disease
 Cancer 2,048 1,074 680 1.0 562
0.87 
(0.77–0.98)
0.03 507
0.74 
(0.56–0.98)
0.03
 Cardiovascular  disease 2,849 1,416 560 1.0 498
0.95 
(0.85–1.06)
0.36 480
0.85 
(0.69–1.05)
0.14
 Other 7,429 2,075 197 1.0 173
0.88 
(0.81–0.97)
0.007a 148
0.81 
(0.68–0.98)
0.03
Morbidity
 Cancer 9,218 2,048 170 1.0 178
1.10 
(1.01–1.21)
0.03 142
0.91 
(0.76–1.10)
0.32
 Cardiovascular  disease 9,218 2,849 137 1.0 132
0.96 
(0.89–1.04)
0.31 128
0.99 
(0.86–1.15)
0.93
 Other 9,214 7,429 589 1.0 586
0.99 
(0.95–1.04)
0.80 607
1.03 
(0.94–1.12)
0.55
Hazard ratios were adjusted for gender and age in all analyses. Numbers of participants vary slightly because some participants were excluded because of development of 
disease before follow-up. International Classifi  cation of Diseases 8 and 10 codes are as follows: for cardiovascular disease, 390-458, I00-I99; and for cancer, 140-209, 
C00-C97. HR, hazard ratio; CI, confi  dence interval.
aPerson-years indicates the number of collective years that the individuals in a particular group were observed.
bRemained statistically signifi  cant (P < 0.05) after Bonferroni correction for multiple comparison for two tests on mortality, six tests on mortality after disease, and six tests 
on morbidity.1298  P53 ARG72PRO, LONGEVITY, AND CANCER | Dynnes Ørsted et al.
Genetic variations in modifi  ers of p53 (ATM and MDM2) 
did not interact with the eff  ect of the Arg72Pro  polymorphism 
on mortality after a diagnosis of cancer (Fig. S4). Infl  ammatory 
conditions and leukocyte activation release nitric oxide, a 
known activator of p53. Therefore, diseases with infl  ammatory 
elements could be particularly aff  ected by the infl  uence of the 
p53 Arg72Pro polymorphism. Interestingly, mortality after a 
diagnosis of respiratory diseases with a known infl  ammatory 
component was reduced in both Arg/Pro heterozygotes and 
Pro/Pro vs. Arg/Arg homozygotes (Table S1, available at http://
www.jem.org/cgi/content/full/jem.20062476/DC1).
Diff  erent cancers have a diff  erent percentage of somatic 
p53 mutations. Therefore, the impact of the Arg72Pro poly-
morphism upon mortality after a cancer diagnosis could de-
pend on cancer subtype with a diff  erent percentage of somatic 
p53 mutations. However, when we regrouped all types of 
cancers in three groups according to frequency of somatic 
p53 mutations as reported for each cancer type by the Inter-
national Agency for Research on Cancer (low, middle, and 
high; references 11–14), the impact of the germline Arg72Pro 
polymorphism upon mortality was independent of frequency 
of somatic p53 mutations (Table S2, available at http://jem
.org/cgi/content/full/jem.20062476/DC1; P = 0.98 on ro-
bust interaction test in Cox regression). Accordingly, for pa-
tients with tumors with high levels of somatic p53 mutations, 
where all the impact in the tumor of the germline Arg72Pro 
polymorphism might be expected to be eliminated, we spec-
ulate that the reduced mortality in Pro/Pro versus Arg/Arg 
homozygotes could be a characteristic of the entire person 
harboring the tumor rather than of the tumor itself.
Risk of cancer
Thereafter, we examined whether the increased longevity by 
TP53 Arg72Pro genotype was explained by decreased risk of 
developing cancer, cardiovascular disease, or other life-threat-
ening disease (Table II). The gender- and age-adjusted hazard 
ratios in Arg/Pro heterozygotes and Pro/Pro versus Arg/Arg 
homozygotes were 1.10 (1.01–1.21) and 0.91 (0.76–1.10) for 
risk of cancer, 0.96 (0.89–1.04) and 0.99 (0.86–1.15) for risk 
of cardiovascular disease, and 0.99 (0.95–1.04) and 1.03 
(0.94–1.12) for risk of other life-threatening diseases, respec-
tively. Furthermore, there was no evidence for decreased risk 
of any cancer subtype in Arg/Pro heterozygotes and Pro/Pro 
versus Arg/Arg homozygotes (Table III). Thus, in accordance 
with a recent study (15), the Arg72Pro substitution did not 
associate with a decreased risk of cancer.
In a recent meta-analysis of 61 individual case-control 
studies with 10,700 cases of mainly cervical, lung, breast, head, 
and neck cancer and 12,300 controls (10), Pro/Pro versus Arg/
Arg homozygotes had an aggregated odds ratio for increased 
cancer risk of 1.11 (95% CI: 1.02–1.22). However, in another 
recent study including nine individual case-control studies 
with 8,700 cases with breast cancer versus 10,600 controls (15), 
Pro/Pro versus Arg/Arg homozygotes had an aggregated 
odds ratio for increased breast cancer risk of 1.03 (0.92–1.15). 
Finally, in our study in the general population, including 
2,000 cases with any cancer subtype and 7,200 individuals 
without cancer during the 55-yr follow-up, we observed a 
hazard ratio of any cancer in Pro/Pro versus Arg/Arg homo-
zygotes of 0.91 (0.76–1.10). Thus, although we only had 40% 
statistical power to exclude a hazard ratio of 1.11 for increased 
risk of cancer in Pro/Pro versus Arg/Arg homozygotes, the 
overall evidence does not favor increased cancer risk in Pro/Pro 
versus Arg/Arg homozygotes.
Surprisingly, the risk of hematologic cancer increased 
twofold in Arg/Pro heterozygotes versus Arg/Arg homozy-
gotes (P < 0.001), with a similar trend in Pro/Pro homozy-
gotes (Table III). This twofold-increased risk was signifi  cant 
even after correction for multiple testing and therefore might 
represent a real rather than a chance fi  nding; however, this 
needs to be confi  rmed in another independent study.
The p53 pathway has elements of sexual dimorphism: 
female Li-Fraumeni patients with p53 mutations develop 
tumors earlier and with a higher frequency when adjusted 
for age (16), and the promoter of MDM2, a p53 interaction 
partner, contains a functional estrogen receptor signal in 
the DNA (17). Therefore, the eff  ect of the p53 Arg72Pro 
polymorphism on risk of cancer in women could depend on 
menopausal status. However, we did not detect any statis-
tically signifi  cant interaction between the Arg72Pro poly-
morphism and gender or menopausal status on risk of cancer 
(Fig. S5, available at http://www.jem.org/cgi/content/full/ 
jem.20062476/DC1).
Potential limitations
For all the analyses described, multifactorial adjustment for 
other potential confounders, as shown in Table I, did not 
Figure 2.  5-yr survival of the general population after a cancer 
diagnosis by p53 Arg72Pro genotype. Cancer diagnosis and death 
endpoints were collected from the Danish Cancer Registry and the Danish 
Civil Registration System, which are 98 and 100% complete. Only cancers 
diagnosed 1 yr before blood sampling and afterward were included. 
(A) For 5-yr survival after a cancer diagnosis, follow-up started at cancer 
diagnosis and ended at death, emigration, or March 11, 2004, whichever 
came fi  rst. (B) Effect of p53 Arg72Pro genotype on 5-yr survival after a 
cancer diagnosis. Arg/Arg homozygotes are in blue, Arg/Pro heterozygotes 
are in red, and Pro/Pro homozygotes are in green.JEM VOL. 204, June 11, 2007  1299
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change the estimates (unpublished data). Furthermore, be-
cause of Mendelian randomization, our results are unlikely to 
be confounded by yet other environmental or lifestyle factors 
(18). Finally, because the p53 Arg72Pro polymorphism is 
well known to be functional at the cellular level, infl  uencing 
apoptotic potential as well as cellular arrest in G1 of the cell 
cycle (5–7), the eff  ects observed in the present study are most 
likely directly due to the Arg72Pro polymorphism rather 
than to another polymorphism nearby in linkage disequilib-
rium with this polymorphism.
Although performed in a large, well-characterized co-
hort of the general population with long-term follow-up 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20062476/DC1), our study has limitations. Because par-
ticipants were only genotyped if they participated in the 
1991–1994 examination of the Copenhagen City Heart 
Study, a selection bias might have occurred if death or mor-
bidity prevented certain individuals from participating in this 
examination. However, we found Hardy-Weinberg equi-
librium in the genotype distribution, making selection bias 
against any of the genotypes unlikely. Should selection bias 
have occurred in this study, it would tend to result in a con-
servative estimate concerning mortality, and therefore cannot 
explain our result. Misclassifi  cation of disease status, but not 
mortality, could also have occurred. However, such misclas-
sifi  cation most likely is minimal because we have 100% follow-
up of the participants and because systematic registration of 
diseases causing hospitalization as well as death are registered 
in the entire country.
Mechanism
p53 can act through several pathways when reacting to cellu-
lar stress. Apoptosis, cell cycle arrest at the G1 checkpoint, 
and cellular senescence are all mechanisms triggered by acti-
vated p53 (19). These mechanisms are all benefi  cial when the 
organism is young, but in older organisms, such eff  ects prob-
ably reduce longevity and augment cancer risk (20), so-called 
antagonistic pleiotropy (19, 21). In accordance with this con-
cept, p53 accelerates aging when responding to cellular stress 
(22). The Arg allele of the Arg72Pro polymorphism increases 
p53-induced apoptosis, whereas the Pro allele eff  ectuates cell 
cycle arrest in the G1 phase (5–7). Our fi  ndings suggest that 
Arg/Pro heterozygotes and Pro/Pro versus Arg/Arg homo-
zygotes have reduced mortality, which could result from 
a generally decreased aging process caused by decreased 
proapoptotic activity and increased cell cycle–arresting abili-
ties of p53.
Conclusions
Although our results suggest that p53 Arg72Pro is not asso-
ciated with risk of cancer or any other disease, this polymor-
phism has a profound gene dose–dependent benefi  cial eff  ect 
on 5-yr survival after a diagnosis of cancer, on survival after 
other life-threatening diseases, and on longevity. Thus, the 
increased longevity may be due to a general increased robust-
ness after a diagnosis of any life-threatening disease. We spec-
ulate that the decreased proapoptotic and increased cell 
cycle–arresting abilities of the Pro versus Arg allele (5–7) 
might be benefi  cial for a person experiencing any critical ill-
ness. This suggests that the TP53 Arg72Pro polymorphism is 
an important gain-of-function genetic variant aff  ecting the 
entire person.
MATERIALS AND METHODS
Using a prospective study of the Danish general population, we examined 
9,219 participants ages 20–95 yr from the Copenhagen City Heart Study 
Table III.  Risk of cancer subgroups according to p53 Arg72Pro genotype in the general population
Arg/Arg Arg/Pro Pro/Pro
Endpoint Participants Events HR
HR 
(95% CI)
p-value
HR 
(95% CI)
p-value
Gastrointestinal cancer 9,219 391 1.0
1.10 
(0.89–1.34)
0.38
0.89 
(0.58–1.37)
0.59
Hematologic cancer 9,218 112 1.0
2.01 
(1.36–2.98) <0.001a 1.49 
(0.70–3.17)
0.30
Respiratory cancer 9,219 271 1.0
0.91 
(0.71–1.17)
0.47
0.82 
(0.49–1.38)
0.46
Urologic cancer 9,217 185 1.0
1.10 
(0.82–1.48)
0.53
0.73 
(0.37–1.45)
0.37
Female cancer 5,155 477 1.0
1.06 
(0.88–1.28)
0.51
0.71 
(0.46–1.07)
0.10
Male cancer 4,114 136 1.0
1.11 
(0.79–1.58)
0.55
1.15 
(0.59–2.23)
0.68
Other cancer 9,219 659 1.0
1.09 
(0.93–1.28)
0.30
1.00 
(0.73–1.37)
0.98
Hazard ratios were adjusted for gender (when relevant) and age in all analyses. Follow-up started January 1, 1947, at the establishment of the Danish Cancer Registry or 
at birth, whichever came last, and ended at the date of the fi  rst relevant cancer diagnosis, death, emigration, or December 31, 2002, whichever came fi  rst. Numbers of 
participants vary slightly because some participants were excluded as a result of the development of disease before follow-up. HR, hazard ratio; CI, confi  dence interval.
aRemained statistically signifi  cant (P < 0.05) after Bonferroni correction for multiple comparison for 14 tests.1300  P53 ARG72PRO, LONGEVITY, AND CANCER | Dynnes Ørsted et al.
participating in the 1991–1994 examination (Fig. S1; references 23–25). 
Height and weight were measured, and participants were questioned about 
smoking habits, alcohol consumption, and physical activity. Blood was drawn 
for cholesterol measurement and DNA extraction. All participants gave writ-
ten informed consent. Herlev University Hospital and the Danish ethical 
committee of Copenhagen and Frederiksberg approved the study (No. 
100.2039/91), which was conducted according to the Helsinki Declaration.
Endpoints. We collected information on morbidity and mortality from 
three diff  erent population registries: information on mortality (23) was ob-
tained from the Danish Civil Registration System; information on morbidity 
was obtained from the Danish National Hospital Discharge Register (26) 
and subdivided according to the Global Burden of Disease classifi  cation (27); 
and information on diagnoses of invasive cancer was obtained from the 
Danish Cancer Registry (28).
Cancer diagnoses were classifi  ed according to criteria from the Interna-
tional Classifi  cation of Diseases, Seventh Edition (29), and divided into seven 
diff  erent subgroups: (a) gastrointestinal cancer, including oral, esophagus, 
stomach, small intestine, liver and biliary tract, pancreatic, colon, rectum, 
and anal cancer; (b) hematologic cancer, including non-Hodgkin’s lym-
phoma, Hodgkin’s disease, multiple myeloma, and leukemia; (c) respira-
tory cancer, including larynx and lung cancer; (d) urologic cancer, including 
kidney and bladder cancer; (e) female cancer, including breast, cervix uteri, 
corpus uteri, ovarian, and vaginal cancer; (f) male cancer, including testis and 
prostate cancer; and (g) other cancers, including melanoma, nonmelanoma 
skin cancer, sarcoma, brain, and other central nervous system cancers, thy-
roid and other endocrine cancers, metastasis with unknown primary tumors, 
and other tumors.
Genotyping. We genotyped 9,219 participants for p53 Arg72Pro, an amino 
acid–changing polymorphism caused by a G215C substitution. By PCR, a 
331-basepair fragment, corresponding to exon 4, was amplifi  ed from ge-
nomic DNA using an intronic forward and exonic reverse primer (forward, 
5′-C  A  T  C  T  A  C  A  G  T  C  C  C  C  C  T  T  G  C  -3′; reverse, 5-G  C  T  T  C  C  A  T  G  A  G  A-
C  T  T  C  A  A  T  G  C  C  -3′). After thermo cycling, genotypes were determined 
using the Nanogen system (30). ATM and MDM2 polymorphisms were 
genotyped using endpoint PCR (Taqman; Applied Biosystems). Probes and 
primers were designed by using Primer Express software (Applied Bio-
systems) and are available from the authors upon request.
Statistical analysis. The statistical software STATA (version 8.2) was used. 
Two-tailed P < 0.05 was considered signifi  cant. We used Mann-Whitney U 
test and Pearson’s χ2 test. Kaplan-Meier curves plotted overall survival and 
survival after a cancer diagnosis as a function of follow-up time as well as 
left-truncated age. Hazard ratios for morbidity and mortality were calculated 
using Cox proportional hazards regression analysis. We tested for propor-
tionality of hazards over time to ensure that this assumption of the Cox pro-
portional hazards regression model was fulfi  lled based on Schonefeld residuals. 
Individuals with endpoints developed before study entry were excluded 
from analysis.
Multifactorial adjustments for cardiovascular and other disease included 
gender, age, tobacco consumption, smoking habits, systolic blood pressure, 
alcohol consumption, total cholesterol, body mass index, and physical activ-
ity at the time of blood sampling. Multifactorial adjustment for risk of cancer 
included the aforementioned variables excluding total cholesterol and sys-
tolic blood pressure.
Online supplemental material. Fig. S1 shows the design of the study. Fig. 
S2 shows p53 Arg72Pro genotype frequency as a function of age in the gen-
eral population. Fig. S3 shows the frequency of the p53 Arg72Pro Pro allele 
and frequency of deaths per 5-yr age group as functions of age. Fig. S4 shows 
the overall hazard ratio of death and the hazard ratio of death after a cancer 
diagnosis by Arg72Pro genotype, stratifi  ed by two ATM genotypes and one 
MDM2 genotype. Fig. S5 shows risk of cancer and cancer subgroups by 
Arg72Pro genotype, stratifi  ed by gender and menopausal status. Table S1 
shows mortality after other diseases and morbidity of other diseases accord-
ing to p53 Arg72Pro genotype in the general population. Table S2 shows 
mortality after a diagnosis of cancer according to low, middle, and high p53 
somatic mutation frequencies and p53 Arg72Pro germline genotype in the 
general population. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20062476/DC1.
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